FP-1039
FP1039-002
Phase 2 small_molecule terminated
Quick answer
FP-1039 for Endometrial Cancers With FGFR2 Mutations is a Phase 2 program (small_molecule) at Prime Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Prime Medicine
- Indication
- Endometrial Cancers With FGFR2 Mutations
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated